Daily pistachios for people taking GLP-1 weight-loss medicines
Dietary Pistachio Intake and Nutrition-Related Outcomes in Individuals Using GLP-1 Receptor Agonists: A Randomized Controlled Trial
This 12-week test will see if eating pistachios every day helps adults on GLP-1 medicines feel fuller, have more energy, and improve weight and diet quality.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 108 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | University Hospitals Cleveland Medical Center Academic / other |
| Locations | 1 site (Clevland, Ohio) |
| Trial ID | NCT07244445 on ClinicalTrials.gov |
What this trial studies
Adults who have been taking GLP‑1 receptor agonists such as semaglutide or tirzepatide for at least three months will add pistachios to their meals for 12 weeks while remaining on their medication. Researchers will measure appetite and eating enjoyment, track diet quality and weight-related outcomes, and perform DEXA scans to assess body composition changes. Blood markers and patient-reported tiredness/energy will also be collected to look for metabolic or wellbeing effects. The protocol focuses on a defined population already using GLP‑1 therapy to see if a simple dietary change adds measurable benefits.
Who should consider this trial
Good fit: Adults with BMI ≥30 kg/m2 (or ≥27 kg/m2 with a weight-related comorbidity) who have used semaglutide or tirzepatide continuously for at least three months and are not allergic to nuts.
Not a fit: People with a nut allergy, those not using GLP‑1 therapy, pregnant or breastfeeding individuals, and incarcerated persons are excluded and would not be eligible to benefit from this protocol.
Why it matters
Potential benefit: If successful, daily pistachio intake could improve fullness, energy, diet quality, and body composition for people using GLP‑1 medicines.
How similar studies have performed: Previous research has linked nut consumption, including pistachios, to improved satiety and diet quality, but studying daily pistachio use specifically in people already on GLP‑1 medications is relatively new.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals with a BMI ≥30 kg/m2 or with a BMI ≥27 kg/m2 with at least one weight-related comorbidity who have been continuously using semaglutide or tirzepatide for three months for a clinical indication and remain on the therapy at the time of enrollment Exclusion Criteria: * No use or contraindication to use of a GLP-1 RA * Known allergy to nuts * Pregnant or breastfeeding * Incarcerated
Where this trial is running
Clevland, Ohio
- University Hospitals Cleveland Medical Center — Clevland, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Ian Neeland, MD — University Hospitals Cleveland Medical Center
- Study coordinator: Ian Neeland, MD
- Email: Ian.Neeland@UHhospitals.org
- Phone: 216-844-5965
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.